Viewing Study NCT00035035

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:31 PM
Ignite Modification Date: 2026-05-07 @ 5:43 PM
Study NCT ID: NCT00035035
Status: COMPLETED
Last Update Posted: 2006-07-19
First Post: 2002-05-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Neoplasms View
None Metastases, Neoplasm View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pancreas View
None Cancer View
None Unresectable or Metastatic Cancer of the Pancreas View
None Alimta View